Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models 2010

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health plans, health technology assessment (HTA) & physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increase in the range of expensive drugs and technologies available as potential therapies. In light of this, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

In terms of innovative agreements, risk-sharing, pay for performance and value-based schemes are being proposed more often by more manufacturers, in more countries. Such agreements are increasingly being seen as a method in which pharma and medical device companies can obtain HTA approval to finance the drug from limited budgets, but also a strategy to gain a competitive advantage and preferential market access.

Why attend?

- Understand the opportunities, obstacles and challenges in designing and implementing innovative agreements.
- Find out when risk-sharing & value based agreements are required and how they can be designed to satisfy all stakeholders to gain market access.
- Understand whether or not the turbulent macroeconomic environment and healthcare reform will increase payer motivation for flexible agreements.
- Obtain the best and most focused picture of risk-sharing and value-based pricing models today.
- Understand the best ways to communicate value and achieve maximum patient and market access.
- Hear the perspectives of all stakeholder groups: Payers, regulators, insurers, health economists and the pharmaceutical industry.
- Discover how payers are evaluating conditional reimbursement agreements.
- Discover if successful